Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Internal Medicine Neurology Oncology Pediatrics Respiratory Medicine Surgery
Congress Coverage
2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting

Keynote Webinar | Spotlight on Diet and Diabetes

Watch on-demand

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. 
ADVANCED SEARCH
Log in
Top
Neurocritical Care

22-09-2023 | Nimodipine | Practice Guidance for Critical Care Management of SAH

Pharmacological Prevention of Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage

Authors: Meghan M. Caylor, R. Loch Macdonald

Published in: Neurocritical Care

Login to get access

Abstract

Background

Causes of morbidity and mortality following aneurysmal subarachnoid hemorrhage (aSAH) include early brain injury and delayed neurologic deterioration, which may result from delayed cerebral ischemia (DCI). Complex pathophysiological mechanisms underlie DCI, which often includes angiographic vasospasm (aVSP) of cerebral arteries.

Methods

Despite the study of many pharmacological therapies for the prevention of DCI in aSAH, nimodipine—a dihydropyridine calcium channel blocker—remains the only drug recommended universally in this patient population. A common theme in the research of preventative therapies is the use of promising drugs that have been shown to reduce the occurrence of aVSP but ultimately did not improve functional outcomes in large, randomized studies. An example of this is the endothelin antagonist clazosentan, although this agent was recently approved in Japan.

Results

The use of the only approved drug, nimodipine, is limited in practice by hypotension. The administration of nimodipine and its counterpart nicardipine by alternative routes, such as intrathecally or formulated as prolonged release implants, continues to be a rational area of study. Additional agents approved in other parts of the world include fasudil and tirilazad.

Conclusions

We provide a brief overview of agents currently being studied for prevention of aVSP and DCI after aSAH. Future studies may need to identify subpopulations of patients who can benefit from these drugs and perhaps redefine acceptable outcomes to demonstrate impact.
Literature
1.
Osgood ML. Aneurysmal subarachnoid hemorrhage: review of the pathophysiology and management strategies. Curr Neurol Neurosci Rep. 2021;21(9):50. PubMedCrossRef
2.
Macdonald RL. Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol. 2014;10(1):44–58. PubMedCrossRef
3.
Vergouwen MD, Vermeulen M, van Gijn J, et al. Definition of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage as an outcome event in clinical trials and observational studies: proposal of a multidisciplinary research group. Stroke. 2010;41(10):2391–5. PubMedCrossRef
4.
Geraghty JR, Testai FD. Delayed cerebral ischemia after subarachnoid hemorrhage: beyond vasospasm and towards a multifactorial pathophysiology. Curr Atheroscler Rep. 2017;19(12):50. PubMedCrossRef
5.
6.
Maher M, Schweizer TA, Macdonald RL. Treatment of spontaneous subarachnoid hemorrhage: guidelines and gaps. Stroke. 2020;51(4):1326–32. PubMedCrossRef
7.
Dorsch NW, King MT. A review of cerebral vasospasm in aneurysmal subarachnoid haemorrhage Part I: incidence and effects. J Clin Neurosci. 1994;1(1):19–26. PubMedCrossRef
8.
Rigante L, van Lieshout JH, Vergouwen MDI, et al. Time trends in the risk of delayed cerebral ischemia after subarachnoid hemorrhage: a meta-analysis of randomized controlled trials. Neurosurg Focus. 2022;52(3):E2. PubMedCrossRef
9.
Boulouis G, Labeyrie MA, Raymond J, et al. Treatment of cerebral vasospasm following aneurysmal subarachnoid haemorrhage: a systematic review and meta-analysis. Eur Radiol. 2017;27(8):3333–42. PubMedCrossRef
10.
Lee H, Perry JJ, English SW, et al. Clinical prediction of delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage. J Neurosurg. 2018;66:1–8.
11.
Stienen MN, Germans M, Burkhardt JK, et al. Predictors of in-hospital death after aneurysmal subarachnoid hemorrhage: analysis of a Nationwide Database (Swiss SOS [Swiss Study on Aneurysmal Subarachnoid Hemorrhage]). Stroke. 2018;49(2):333–40. PubMedCrossRef
12.
Crowley RW, Medel R, Dumont AS, et al. Angiographic vasospasm is strongly correlated with cerebral infarction after subarachnoid hemorrhage. Stroke. 2011;42(4):919–23. PubMedCrossRef
13.
Frontera JA, Fernandez A, Schmidt JM, et al. Defining vasospasm after subarachnoid hemorrhage: what is the most clinically relevant definition? Stroke. 2009;40(6):1963–8. PubMedCrossRef
14.
Frontera JA, Claassen J, Schmidt JM, et al. Prediction of symptomatic vasospasm after subarachnoid hemorrhage: the modified fisher scale. Neurosurgery 2006;59(1):21–7; discussion 21–7.
15.
van der Steen WE, Marquering HA, Boers AMM, et al. Predicting delayed cerebral ischemia with quantified aneurysmal subarachnoid blood volume. World Neurosurg. 2019;130:e613–9. PubMedCrossRef
16.
de Rooij NK, Greving JP, Rinkel GJ, Frijns CJ. Early prediction of delayed cerebral ischemia after subarachnoid hemorrhage: development and validation of a practical risk chart. Stroke. 2013;44(5):1288–94. PubMedCrossRef
17.
de Oliveira Manoel AL, Jaja BN, Germans MR, et al. The VASOGRADE: a simple grading scale for prediction of delayed cerebral ischemia after subarachnoid hemorrhage. Stroke. 2015;46(7):1826–31. PubMedCrossRef
18.
Fang YJ, Mei SH, Lu JN, et al. New risk score of the early period after spontaneous subarachnoid hemorrhage: for the prediction of delayed cerebral ischemia. CNS Neurosci Ther. 2019;25(10):1173–81. PubMedPubMedCentralCrossRef
19.
Crobeddu E, Mittal MK, Dupont S, Wijdicks EF, Lanzino G, Rabinstein AA. Predicting the lack of development of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Stroke. 2012;43(3):697–701. PubMedCrossRef
20.
Reilly C, Amidei C, Tolentino J, Jahromi BS, Macdonald RL. Clot volume and clearance rate as independent predictors of vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2004;101(2):255–61. PubMedCrossRef
21.
Mishra S, Garg K, Gaonkar VB, et al. Effects of various therapeutic agents on vasospasm and functional outcome after aneurysmal subarachnoid hemorrhage-results of a network meta-analysis. World Neurosurg. 2021;155:41–53. PubMedCrossRef
22.
Dayyani M, Sadeghirad B, Grotta JC, et al. Prophylactic therapies for morbidity and mortality after aneurysmal subarachnoid hemorrhage: a systematic review and network meta-analysis of randomized trials. Stroke. 2022;53(6):1993–2005. PubMedCrossRef
23.
Treggiari MM, Rabinstein AA, Busl KM, et al. Guidelines for the neurocritical care management of aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2022;6:66.
24.
Shen J, Zhu K, Zhou H, Tian H, Yu G. Efficacy of statins in cerebral vasospasm, mortality, and delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis of randomized controlled trials. World Neurosurg. 2019;131:e65–73. PubMedCrossRef
25.
Etminan N, Vergouwen MD, Ilodigwe D, Macdonald RL. Effect of pharmaceutical treatment on vasospasm, delayed cerebral ischemia, and clinical outcome in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Cereb Blood Flow Metab. 2011;31(6):1443–51. PubMedPubMedCentralCrossRef
26.
Reddy D, Fallah A, Petropoulos JA, Farrokhyar F, Macdonald RL, Jichici D. Prophylactic magnesium sulfate for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. Neurocrit Care. 2014;21(2):356–64. PubMedCrossRef
27.
Casaubon LK, Boulanger JM, Blacquiere D, et al. Canadian stroke best practice recommendations: hyperacute stroke care guidelines, update 2015. Int J Stroke. 2015;10(6):924–40. PubMedCrossRef
28.
Cho WS, Kim JE, Park SQ, et al. Korean Clinical Practice Guidelines for aneurysmal subarachnoid hemorrhage. J Korean Neurosurg Soc. 2018;61(2):127–66. PubMedPubMedCentralCrossRef
29.
Committee for Guidelines for Management of Aneurysmal Subarachnoid Hemorrhage JpSoSfCS. Evidence-based guidelines for the management of aneurysmal subarachnoid hemorrhage. English Edition. Neurol Med Chir. 2012;52(6):355–429.
30.
Connolly ES, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association. Stroke. 2012;43(6):1711–37. PubMedCrossRef
31.
Steiner T, Juvela S, Unterberg A, et al. European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis. 2013;35(2):93–112. PubMedCrossRef
32.
Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ. 1989;298(6674):636–42. PubMedPubMedCentralCrossRef
33.
Petruk KC, West M, Mohr G, et al. Nimodipine treatment in poor-grade aneurysm patients. Results of a multicenter double-blind placebo-controlled trial. J Neurosurg. 1988;68(4):505–17. PubMedCrossRef
34.
Allen GS, Ahn HS, Preziosi TJ, et al. Cerebral arterial spasm–a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. 1983;308(11):619–24. PubMedCrossRef
35.
Ohman J, Servo A, Heiskanen O. Long-term effects of nimodipine on cerebral infarcts and outcome after aneurysmal subarachnoid hemorrhage and surgery. J Neurosurg. 1991;74(1):8–13. PubMedCrossRef
36.
Philippon J, Grob R, Dagreou F, Guggiari M, Rivierez M, Viars P. Prevention of vasospasm in subarachnoid haemorrhage. A controlled study with nimodipine. Acta Neurochir. 1986;82(3–4):110–4. PubMedCrossRef
37.
Mee E, Dorrance D, Lowe D, Neil-Dwyer G. Controlled study of nimodipine in aneurysm patients treated early after subarachnoid hemorrhage. Neurosurgery. 1988;22(3):484–91. PubMedCrossRef
38.
Kostron H, Twerdy K, Grunert V. The calcium entry blocker nimodipine improves the quality of life of patients operated on for cerebral aneurysms. A 5-year follow-up analysis. Neurochirurgia. 1988;31(5):150–3. PubMed
39.
Brandt L, Säveland H, Romner B, Ryman T. Does nimodipine eliminate arterial hypertension as a prognostic risk factor in subarachnoid haemorrhage? Br J Neurosurg. 1991;5(5):485–9. PubMedCrossRef
40.
Popovic EA, Danks RA, Siu KH. Experience with nimodipine in aneurysmal subarachnoid haemorrhage. Med J Aust. 1993;158(2):91–4. PubMedCrossRef
41.
Mijailovic M, Lukic S, Laudanovic D, Folic M, Folic N, Jankovic S. Effects of nimodipine on cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage treated by endovascular coiling. Adv Clin Exp Med. 2013;22(1):101–9. PubMed
42.
Seiler RW, Grolimund P, Zurbruegg HR. Evaluation of the calcium-antagonist nimodipine for the prevention of vasospasm after aneurysmal subarachnoid haemorrhage. A prospective transcranial Doppler ultrasound study. Acta Neurochir. 1987;85(1–2):7–16. PubMedCrossRef
43.
Barker FG, Ogilvy CS. Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: a metaanalysis. J Neurosurg. 1996;84(3):405–14. PubMedCrossRef
44.
MacKenzie M, Gorman SK, Doucette S, Green R. Incidence of and factors associated with manipulation of nimodipine dosage in patients with aneurysmal subarachnoid hemorrhage. Can J Hosp Pharm. 2014;67(5):358–65. PubMedPubMedCentral
45.
Wessell A, Kole MJ, Badjatia N, et al. High compliance with scheduled nimodipine is associated with better outcome in aneurysmal subarachnoid hemorrhage patients cotreated with heparin infusion. Front Neurol. 2017;8:268. PubMedPubMedCentralCrossRef
46.
Sandow N, Diesing D, Sarrafzadeh A, Vajkoczy P, Wolf S. Nimodipine dose reductions in the treatment of patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2016;25(1):29–39. PubMedCrossRef
47.
Hajizadeh Barfejani A, Rabinstein AA, Wijdicks EFM, Clark SL. Poor utilization of nimodipine in aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis. 2019;28(8):2155–8. PubMedCrossRef
48.
Hernández-Durán S, Mielke D, Rohde V, Malinova V. Does nimodipine interruption due to high catecholamine doses lead to a greater incidence of delayed cerebral ischemia in the setting of aneurysmal subarachnoid hemorrhage? World Neurosurg. 2019;132:e834–40. PubMedCrossRef
49.
50.
Hänggi D, Etminan N, Steiger HJ, et al. A site-specific, sustained-release drug delivery system for aneurysmal subarachnoid hemorrhage. Neurotherapeutics. 2016;13(2):439–49. PubMedPubMedCentralCrossRef
51.
Hänggi D, Etminan N, Aldrich F, et al. Randomized, open-label, phase 1/2a study to determine the maximum tolerated dose of intraventricular sustained release nimodipine for subarachnoid hemorrhage (NEWTON [Nimodipine Microparticles to Enhance Recovery While Reducing Toxicity After Subarachnoid Hemorrhage]). Stroke. 2017;48(1):145–51. PubMedCrossRef
52.
Carlson AP, Hänggi D, Wong GK, et al. Single-dose intraventricular nimodipine microparticles versus oral nimodipine for aneurysmal subarachnoid hemorrhage. Stroke. 2020;51(4):1142–9. PubMedCrossRef
53.
Sadan O, Waddel H, Moore R, et al. Does intrathecal nicardipine for cerebral vasospasm following subarachnoid hemorrhage correlate with reduced delayed cerebral ischemia? A retrospective propensity score-based analysis. J Neurosurg. 2022;136(1):115–24. PubMedCrossRef
54.
Kuroi Y, Ohbuchi H, Arai N, et al. Twelve-year single critical care center experience of nicardipine prolonged-release implants in patients with subarachnoid hemorrhage: a propensity score matching analysis. J Neurointerv Surg. 2020;12(8):774–6. PubMedCrossRef
55.
Kasuya H, Onda H, Sasahara A, Takeshita M, Hori T. Application of nicardipine prolonged-release implants: analysis of 97 consecutive patients with acute subarachnoid hemorrhage. Neurosurgery. 2005;56(5):895–902. PubMed
56.
Barth M, Capelle HH, Weidauer S, et al. Effect of nicardipine prolonged-release implants on cerebral vasospasm and clinical outcome after severe aneurysmal subarachnoid hemorrhage: a prospective, randomized, double-blind phase IIa study. Stroke. 2007;38(2):330–6. PubMedCrossRef
57.
Shibuya M, Suzuki Y, Enomoto H, Okada T, Ogura K, Sugita K. Effects of prophylactic intrathecal administrations of nicardipine on vasospasm in patients with severe aneurysmal subarachnoid haemorrhage. Acta Neurochir. 1994;131(1–2):19–25. PubMedCrossRef
58.
Hino A, Tokuyama Y, Kobayashi M, et al. Increased expression of endothelin B receptor mRNA following subarachnoid hemorrhage in monkeys. J Cereb Blood Flow Metab. 1996;16(4):688–97. PubMedCrossRef
59.
Roux S, Breu V, Giller T, et al. Ro 61–1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm. J Pharmacol Exp Ther. 1997;283(3):1110–8. PubMed
60.
Macdonald RL, Kassell NF, Mayer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke. 2008;39(11):3015–21. PubMedCrossRef
61.
Macdonald RL, Higashida RT, Keller E, et al. Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials. Neurocrit Care. 2010;13(3):416–24. PubMedCrossRef
62.
Macdonald RL, Higashida RT, Keller E, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol. 2011;10(7):618–25. PubMedCrossRef
63.
Macdonald RL, Higashida RT, Keller E, et al. Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling. Stroke. 2012;43(6):1463–9. PubMedCrossRef
64.
Song J, Xue YQ, Wang YJ, Xu P, Sun DK, Chen W. An update on the efficacy and safety profile of clazosentan in cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a meta-analysis. World Neurosurg. 2019;123:e235–44. PubMedCrossRef
65.
Fujimura M, Joo JY, Kim JS, Hatta M, Yokoyama Y, Tominaga T. Preventive effect of clazosentan against cerebral vasospasm after clipping surgery for aneurysmal subarachnoid hemorrhage in Japanese and Korean Patients. Cerebrovasc Dis. 2017;44(1–2):59–67. PubMedCrossRef
66.
Endo H, Hagihara Y, Kimura N, et al. Effects of clazosentan on cerebral vasospasm-related morbidity and all-cause mortality after aneurysmal subarachnoid hemorrhage: two randomized phase 3 trials in Japanese patients. J Neurosurg. 2022;66:1–11.
67.
68.
Hall ED. Inhibition of lipid peroxidation in central nervous system trauma and ischemia. J Neurol Sci. 1995;134(Suppl):79–83. PubMedCrossRef
69.
Jang YG, Ilodigwe D, Macdonald RL. Metaanalysis of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2009;10(1):141–7. PubMedCrossRef
70.
Maruhashi T, Higashi Y. An overview of pharmacotherapy for cerebral vasospasm and delayed cerebral ischemia after subarachnoid hemorrhage. Expert Opin Pharmacother. 2021;22(12):1601–14. PubMedCrossRef
71.
Zhao J, Zhou D, Guo J, et al. Effect of fasudil hydrochloride, a protein kinase inhibitor, on cerebral vasospasm and delayed cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage. Neurol Med Chir. 2006;46(9):421–8. CrossRef
72.
Zhao J, Zhou D, Guo J, et al. Efficacy and safety of fasudil in patients with subarachnoid hemorrhage: final results of a randomized trial of fasudil versus nimodipine. Neurol Med Chir. 2011;51(10):679–83. CrossRef
73.
Shibuya M, Suzuki Y, Sugita K, et al. Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid haemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg. 1992;76(4):571–7. PubMedCrossRef
74.
Iwabuchi S, Yokouchi T, Hayashi M, et al. Intra-arterial administration of fasudil hydrochloride for vasospasm following subarachnoid haemorrhage: experience of 90 cases. Acta Neurochir Suppl. 2011;110(Pt 2):179–81. PubMed
75.
Kuwano A, Ishiguro T, Nomura S, et al. Predictive factors for improvement of symptomatic cerebral vasospasm following subarachnoid hemorrhage by selective intra-arterial administration of fasudil hydrochloride. Interv Neuroradiol. 2023;6:66.
76.
Saber H, Desai A, Palla M, Mohamed W, Seraji-Bozorgzad N, Ibrahim M. Efficacy of cilostazol in prevention of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage: a meta-analysis. J Stroke Cerebrovasc Dis. 2018;27(11):2979–85. PubMedCrossRef
77.
Bohara S, Garg K, Singh Rajpal PM, Kasliwal M. Role of cilostazol in prevention of vasospasm after aneurysmal subarachnoid hemorrhage-a systematic review, meta-analysis, and trial sequential analysis. World Neurosurg. 2021;150:161–70. PubMedCrossRef
78.
Matsuda N, Naraoka M, Ohkuma H, et al. Effect of cilostazol on cerebral vasospasm and outcome in patients with aneurysmal subarachnoid hemorrhage: a randomized, double-blind. Placebo-Controlled Trial Cerebrovasc Dis. 2016;42(1–2):97–105. PubMedCrossRef
79.
Czorlich P, Sauvigny T, Ricklefs F, et al. Impact of dexamethasone in patients with aneurysmal subarachnoid haemorrhage. Eur J Neurol. 2017;24(4):645–51. PubMedCrossRef
80.
Mahoney N, Williamson CA, Rothman E, et al. A propensity score analysis of the impact of dexamethasone use on delayed cerebral ischemia and poor functional outcomes after subarachnoid hemorrhage. World Neurosurg. 2018;109:e655–61. CrossRef
81.
Kole MJ, Wessell AP, Ugiliweneza B, et al. Low-dose intravenous heparin infusion after aneurysmal subarachnoid hemorrhage is associated with decreased risk of delayed neurological deficit and cerebral infarction. Neurosurgery. 2021;88(3):523–30. PubMedCrossRef
82.
Raymond J, Darsaut TE, Altman DG. Pragmatic trials can be designed as optimal medical care: principles and methods of care trials. J Clin Epidemiol. 2014;67(10):1150–6. PubMedCrossRef
83.
Darsaut TE, Raymond J. Clinical trials: What are we afraid of, what should we do? J Neurointerv Surg. 2016;8(e1):e14–6. PubMedCrossRef
84.
Takemae T, Mizukami M, Kin H, Kawase T, Araki G. Computed tomography of ruptured intracranial aneurysms in acute stage–relationship between vasospasm and high density on CT scan (author’s transl). No To Shinkei. 1978;30(8):861–6. PubMed
85.
Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery. 1980;6(1):1–9. PubMedCrossRef
86.
Hijdra A, Brouwers PJ, Vermeulen M, van Gijn J. Grading the amount of blood on computed tomograms after subarachnoid hemorrhage. Stroke. 1990;21(8):1156–61. PubMedCrossRef
87.
Brouwers PJ, Wijdicks EF, Van Gijn J. Infarction after aneurysm rupture does not depend on distribution or clearance rate of blood. Stroke. 1992;23(3):374–9. PubMedCrossRef
88.
Claassen J, Bernardini GL, Kreiter K, et al. Effect of cisternal and ventricular blood on risk of delayed cerebral ischemia after subarachnoid hemorrhage: the Fisher scale revisited. Stroke. 2001;32(9):2012–20. PubMedCrossRef
89.
Sato T, Sasaki T, Sakuma J, et al. Quantification of subarachnoid hemorrhage by three-dimensional computed tomography: correlation between hematoma volume and symptomatic vasospasm. Neurol Med Chir. 2011;51(3):187–94. CrossRef
90.
Ko SB, Choi HA, Carpenter AM, et al. Quantitative analysis of hemorrhage volume for predicting delayed cerebral ischemia after subarachnoid hemorrhage. Stroke. 2011;42(3):669–74. PubMedCrossRef
91.
Cremers CH, van der Schaaf IC, Wensink E, et al. CT perfusion and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Cereb Blood Flow Metab. 2014;34(2):200–7. PubMedCrossRef
92.
Ramos LA, van der Steen WE, Sales Barros R, et al. Machine learning improves prediction of delayed cerebral ischemia in patients with subarachnoid hemorrhage. J Neurointerv Surg. 2019;11(5):497–502. PubMedCrossRef
93.
Savarraj JPJ, Hergenroeder GW, Zhu L, et al. Machine learning to predict delayed cerebral ischemia and outcomes in subarachnoid hemorrhage. Neurology. 2021;96(4):e553–62. PubMedPubMedCentralCrossRef
Metadata
Title
Pharmacological Prevention of Delayed Cerebral Ischemia in Aneurysmal Subarachnoid Hemorrhage
Authors
Meghan M. Caylor
R. Loch Macdonald
Publication date
22-09-2023
Publisher
Springer US
Published in
Neurocritical Care
Print ISSN: 1541-6933
Electronic ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-023-01847-6